Khalkhali I, Iraniha S, Diggles L E, Cutrone J A, Mishkin F S
Department of Radiology, Harbor University of California, Los Angeles Medical Center, Torrance, USA.
Q J Nucl Med. 1997 Sep;41(3):231-8.
Technetium-99-Sestamibi scintimammography has emerged as a new procedure for the imaging of breast tumors. Currently, a large clinical experience has been developed and the results published. At the present time, the major drawback of this procedure appears to be its low sensitivity for the detection of breast carcinomas smaller than 1 cm in diameter. There are other biologic and technical issues that remain to be overcome to optimally image the breasts. Some of these include: development of a dedicated breast imager using nuclear medicine techniques, development of stereotactic needle localization of the abnormalities that demonstrate focal increase uptake in women with normal mammogram and breast physical examination, manufacturing of a breast compression device so that we can immobilize the breast in place for more adequate imaging, overcoming the issue of unilateral or bilateral diffuse breast uptake that is noted in 7-10 percent of the cases and finally, determination of optimal dose and imaging factors. This review includes our experience at Harbor-University of California, Los Angeles Medical Center with the use of this agent for breast imaging since 1992.
锝-99-甲氧基异丁基异腈闪烁乳腺造影已成为一种用于乳腺肿瘤成像的新方法。目前，已经积累了大量临床经验并发表了相关结果。目前，该方法的主要缺点似乎是对直径小于1厘米的乳腺癌检测灵敏度较低。还有其他生物学和技术问题有待克服，以便对乳房进行最佳成像。其中一些问题包括：利用核医学技术开发专用乳腺成像仪，对乳腺X线摄影和乳腺体格检查正常但显示局灶性摄取增加的异常情况进行立体定向针定位，制造乳腺压迫装置以便能够将乳房固定到位以进行更充分的成像，克服7%-10%的病例中出现的单侧或双侧乳腺弥漫性摄取问题，以及最后确定最佳剂量和成像参数。这篇综述包括了自1992年以来我们在加州大学洛杉矶分校港湾医学中心使用该药物进行乳腺成像的经验。
